Sleep Disorders

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed the importance of identifying and diagnosing obstructive sleep apnea as a prevention for a number of its consequential risk factors.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed the importance of identifying and diagnosing obstructive sleep apnea as a prevention for a number of its consequential risk factors.

The senior director of Global Clinical Science at Takeda Pharmaceutical offered perspective on the development of TAK-925, an investigational selective orexin type-2 receptor agonist for the treatment of narcolepsy.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine spoke about the challenge of OSA being underdiagnosed, and what her institution is doing to combat it.

Neurology News Network for the week ending October 5, 2019.

The chief medical officer at Harmony Biosciences discussed the takeaways from a number of data presentations of pitolisant’s efficacy and safety from World Sleep 2019.

Year-long data presented at World Sleep 2019 suggest that Eisai’s lemborexant is safe and effective in treating adults with insomnia, supporting its recently submitted NDA. It is set to be reviewed by the FDA by late December.

Data presented at World Sleep 2019 has suggested that the investigation Jazz Pharmaceuticals sodium oxybate agent, JZP-258, is efficacious and safe in treating patients with narcolepsy who have cataplexy.

The analyses focus on the abuse potential, efficacy in high-burden patients with narcolepsy, and safety data for Harmony Biosciences’ histamine H3 receptor-antagonist/inverse agonist, pitolisant.

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City.

As new dual orexin receptor antagonists become available to treat sleep disorders, time will tell whether this new class of drugs will fulfill its promise for a disorder plagued by underdiagnosis and indifference.

Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center will offer further insights on narcolepsy at the upcoming International Congress on the Future of Neurology, September 27-28, 2019 in New York City.

The associate chief of the MS division and professor of neurology at the University of Pennsylvania described the relationship between artificial intelligence and medicine, and how he sees it evolving in the future.

Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.